Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer
An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer

NCT01712347

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Colorectal Cancer

Interventions: Bevacizumab, Chemotherapy

Countries: Taiwan

This multicenter observational study will evaluate the efficacy and safety of first-line bevacizumab (Avastin) in combination with fluoropyrimidine-based chemotherapy in participants with metastatic colorectal cancer (mCRC). Participants for whom the treating physician has decided to initiate first-line fluoropyrimidine based chemotherapy in combination with bevacizumab will be observed for approximately 4 years.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Participants with histologically confirmed metastatic colorectal cancer who will receive bevacizumab in combination with first-line fluoropyrimidine-based chemotherapy

Exclusion Criteria:

* Participants not qualified for bevacizumab treatment according to the local label
Locations (9)
  • CHAI YI, Taiwan
  • Kaohsiung City, Taiwan
  • Kaohsiung City, Taiwan
  • Taichung, Taiwan
  • Tainan, Taiwan
  • Taipei, Taiwan
  • Taipei, Taiwan
  • Taipei, Taiwan
  • Taoyuan, Taiwan